Learning objectives: To define the role of immune checkpoint inhibitors in advanced and early-stage triple-negative breast cancer.

To describe immune-related adverse events associated with immune checkpoint inhibitor therapy in early stage breast cancer.

Session date: 
09/21/2021 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Rita Nanda, MD